{
    "clinical_study": {
        "@rank": "164730", 
        "arm_group": {
            "arm_group_label": "Teriparatide", 
            "arm_group_type": "Other", 
            "description": "one arm study. All patients receive teriparatide"
        }, 
        "brief_summary": {
            "textblock": "Study Title:\n\n      A pilot study to evaluate the effect of Forsteo\u00ae (Teriparatide, 1-34 rh-PTH) in Anorexia\n      Nervosa patients with low mineral density and increased bone fragility (FAN-Trial)\n\n      Short Title/Study ID:\n\n      FAN-Trial / Psy-Rheu_2011/1\n\n      Indication:\n\n      Low bone mineral density (Z-Score < -1.5 or T-Score < -1.5 if available) and fragility\n      fractures or very low bone mineral density (Z-Score < -2.5 or T-Score <-2.5 if available)\n      without fragility fractures in Anorexia Nervosa patients\n\n      Trial Design:\n\n      Open-label, single-centre pilot study with study drug treatment duration of 24 months.\n\n      Study Center:\n\n      Single-centre (University Hospital of Z\u00fcrich)\n\n      Investigator(s)/Authors:\n\n      PD Dr. med Gabriella F. Milos (Principle Investigator and author), Dept of Psychiatry,\n      Centre for Eating Disorders, University Hospital Z\u00fcrich, CH-8091 Z\u00fcrich Dr. med. Diana P.\n      Frey (Co-Investigator and author), Dept. of Rheumatology, University Hospital Z\u00fcrich,\n      CH-8091 Z\u00fcrich PD Dr. med. Daniel Uebelhart (author), SUVA Fribourg, CH-1701 Fribourg\n\n      Objective(s)/Outcome(s):\n\n      Primary endpoint:\n\n      \u2022To assess the efficacy of Teriparatide (Forsteo\u00ae) in increasing the bone mineral density in\n      the lumbar spine, total hip and femoral neck in patients with anorexia nervosa and low bone\n      density at months 12 and 24.\n\n      Secondary endpoints:\n\n        -  To assess the changes in blood biomarkers\n\n        -  To assess changes in whole body composition\n\n        -  To assess the incidence of new fragility fractures\n\n        -  To assess changes in bone structure\n\n        -  To assess the changes in EDE-Q\n\n        -  Longterm safety and tolerability of Teriparatide (Forsteo\u00ae)  in patients with AN\n\n      Assessments for primary endpoint:\n\n      \u2022BMD at lumbar spine, total hip and femoral neck, measured by DXA\n\n      Assessments for secondary endpoints:\n\n        -  bone resorption and bone formation markers measured in urine and serum\n\n        -  whole body composition measured by DXA\n\n        -  New clinical peripheral and vertebral fractures\n\n        -  HRqCT of tibia and forearm\n\n        -  EDE-Q Score at months 12 and 24\n\n      Safety measurements:\n\n        -  Safety lab (blood and urine)\n\n        -  Clinical adverse event monitoring at all visits Number of Subjects: 10\n\n      Diagnosis and Main Inclusion Criteria:\n\n        -  Women, aged > 18 to < 35 years\n\n        -  Having severe anorexia nervosa (AN) (DSM-IV-R) for > 12 months before screening\n\n        -  Presenting with very low bone mineral density (defined as Z-Score < -2.5 or T-Score <\n           -2.5 if available) of at least one of the assessed localizations (lumbar spine L1 - L4,\n           total hip, femoral neck) without any previous fragility fracture\n\n        -  or low bone mineral density (defined as Z-Score < -1.5 or T-Score < -1.5 if available)\n           of at least one of the assessed localizations (lumbar spine L1 - L4, total hip, femoral\n           neck) and at least one previous fragility fracture\n\n        -  In- and out-patients of the Centre for Eating Disorders at the Clinic for Psychiatry\n           and Psychotherapy of the University Hospital of Zurich.\n\n      Main Exclusion Criteria:\n\n        -  Metabolic bone diseases other than primary osteoporosis (including hyperparathyroidism,\n           osteomalacia, Paget's disease of bone), pre-existing hypercalcemia, severe renal\n           impairment (GFR < 30 ml/min), prior external beam or implant radiation therapy to the\n           skeleton, skeletal malignancies or bone metastases, any unknown elevation of serum\n           alkaline phosphatase, severe psychiatric diseases other than AN, drug addiction, HIV\n           positive patients, pregnancy, open epiphyses\n\n        -  Incapacity to understand the aims of the study or patients not willing to collaborate.\n\n      Study Product, Dose, Route, Regimen:\n\n      Teriparatide (Forsteo\u00ae), 20\u00b5g s.c. daily for 24 months.\n\n      Duration of study:\n\n      24 months.\n\n      Reference therapy, Dose, Route, Regimen:\n\n      NA\n\n        -  Trial with medicinal product"
        }, 
        "brief_title": "A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial)", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Low Bone Mass in Anorexia Nervosa Patients", 
        "condition_browse": {
            "mesh_term": [
                "Anorexia", 
                "Anorexia Nervosa"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria: \u2022Women, aged > 18 to < 35 years\n\n          -  Having severe anorexia nervosa (AN) (DSM-IV-R) for > 12 months before screening\n\n          -  Presenting with very low bone mineral density (defined as Z-Score < -2.5 or T-Score <\n             -2.5 if available) of at least one of the assessed localizations (lumbar spine L1 -\n             L4, total hip, femoral neck) without any previous fragility fracture\n\n          -  or low bone mineral density (defined as Z-Score < -1.5 or T-Score < -1.5 if\n             available) of at least one of the assessed localizations (lumbar spine L1 - L4, total\n             hip, femoral neck) and at least one previous fragility fracture\n\n          -  In- and out-patients of the Centre for Eating Disorders at the Clinic for Psychiatry\n             and Psychotherapy of the University Hospital of Zurich.\n\n        Exclusion criteria: Metabolic bone diseases other than primary osteoporosis (including\n        hyperparathyroidism, osteomalacia, Paget's disease of bone), pre-existing hypercalcemia,\n        severe renal impairment (GFR < 30 ml/min), prior external beam or implant radiation\n        therapy to the skeleton, skeletal malignancies or bone metastases, any unknown elevation\n        of serum alkaline phosphatase, severe psychiatric diseases other than AN, drug addiction,\n        HIV positive patients, pregnancy, open epiphyses\n\n        \u2022Incapacity to understand the aims of the study or patients not willing to collaborate."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01801397", 
            "org_study_id": "Psy-Rheu_2011/1"
        }, 
        "intervention": {
            "arm_group_label": "Teriparatide", 
            "intervention_name": "osteoanabolic therapy", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Teriparatide"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland", 
                        "state": "ZH", 
                        "zip": "8091"
                    }, 
                    "name": "University Hospital Zurich, Department of Psychiatry"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "diana.frey@usz.ch", 
                    "last_name": "Diana P Frey, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland", 
                        "state": "ZH", 
                        "zip": "8091"
                    }, 
                    "name": "University Hospital Zurich, Rheumatology Department"
                }, 
                "investigator": {
                    "last_name": "Diana P Frey, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "diana.frey@usz.ch", 
            "last_name": "Frey Diana, MD"
        }, 
        "overall_contact_backup": {
            "email": "gabriella.milos@usz.ch", 
            "last_name": "Gabriella Milos, MD"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Zurich, Department of Psychiatry", 
            "last_name": "Gabriella Milos, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To assess the efficacy of Teriparatide (Forsteo\u00ae) in increasing the bone mineral density in the lumbar spine, total hip and femoral neck in patients with anorexia nervosa and low bone density at months 12 and 24.", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01801397"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}